Nebibeta

Quick links to important sections

Nebibeta

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nebibeta

Quick Facts: Nebibeta

Property Description
Active Ingredient Nebivolol (Nebivolol hydrochloride)
Form Tablet (Oral dosage form)
Pharmacological Class Beta-adrenergic receptor blocker (β-blocker)
Generation / Type Third-generation β-blocker with vasodilatory properties
Origin Synthetic (Chemically synthesized)

Defining the Medicinal Agent

Nebibeta is a synthetic, prescription-only cardiovascular medicine whose active component is Nebivolol (as Nebivolol hydrochloride). It is fundamentally categorized as a beta-adrenergic receptor blocker (β-blocker), a class of agents that influence the body’s response to nerve impulses. Specifically, Nebivolol is a highly β₁-selective antagonist, meaning it primarily targets β₁-receptors located in the heart. This classification confirms its principal role in affecting heart rate and blood flow dynamics, and the medication is supplied as a single-entity product intended for systemic administration.

Unique Action and General Purpose

Nebivolol belongs to the third-generation beta-blocker group. This generation is distinguished by an ancillary effect beyond primary receptor blockade: the drug promotes peripheral vasodilation—the widening of blood vessels—by stimulating the release of Nitric Oxide (NO). The general purpose of Nebibeta is therefore to reduce overall resistance and strain within the circulatory network. This dual pharmacological activity—slowing the heart and relaxing the vessels—is the fundamental principle by which the medicine works, offering a mechanism valued in the long-term management of cardiovascular function.

Regulatory References

  1. Beta Blockers - StatPearls - NCBI Bookshelf
  2. Selective Beta-1 Blockers - StatPearls - NCBI Bookshelf

What side effects are possible with Nebibeta?

Possible Side Effects and Safety Information

The official safety information for Nebibeta (Nebivolol) organizes possible adverse reactions based on their frequency and the physiological system affected, providing a descriptive framework of the medicine's risk profile as documented by regulatory authorities.

Adverse effects are formally classified into frequency tiers: Common (1/100 to < 1/10), Uncommon (1/1,000 to < 1/100), and Rare (1/10,000 to < 1/1,000).

Commonly Documented Adverse Reactions

Reported effects appearing in the Common tier often involve the Nervous System and Gastrointestinal Disorders. These include headache, dizziness, fatigue, diarrhea, nausea, and constipation. Vascular effects such as oedema are also cited in this category.

System-Organ Classes and Serious Reactions

Adverse reactions are grouped by system-organ classes, including effects on the Cardiac system (e.g., bradycardia, heart failure, AV block), Vascular system (hypotension, aggravation of claudication), and Respiratory system (dyspnoea, bronchospasm).

The regulatory safety profile explicitly identifies certain rare events as serious adverse reactions. These clinically significant events include Acute Heart Failure, Severe Bradycardia, severe Hypotension, and rare dermatological conditions such as Stevens-Johnson Syndrome.

Safety Restrictions and Population Considerations

The medicine is subject to defined safety restrictions (contraindications) for individuals with certain severe pre-existing conditions. These include uncompensated heart failure, cardiogenic shock, severe bradycardia, second- and third-degree heart block (without a pacemaker), and severe hepatic impairment. Furthermore, official prescribing information notes that use is not recommended in patients with severe renal impairment and advises caution when initiating treatment in patients over 75 years of age.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Nebibeta


Overdose scope

Field Official Regulatory Statement
Documented overdose presentations Clinical manifestations include severe bradycardia, profound hypotension, acute cardiac failure, bronchospasm, vertigo, and syncope (fainting).
Physiological systems affected (as stated in label) Cardiovascular System (hypotension, cardiac failure), Respiratory System (bronchospasm), Central Nervous System (vertigo, potential for coma).
Dose-related or exposure-related factors (if applicable) The official label addresses the consequences of overdosage but does not specify a definitive minimum toxic dose level.
Population-specific overdose notes (if applicable) No unique, differentiated management strategies are consistently documented based solely on population factors.
Emergency-response statements (as written in official documents) Seek immediate medical attention upon suspicion of overdosage.
When immediate medical help is required (label-derived phrasing only) Immediately for severe or life-threatening symptoms, or upon suspicion of overdosage.

Overdose classifications (high-level)

Field Official Regulatory Statement
Severity classification (as defined in official documents) Overdosage may lead to life-threatening outcomes, including cardiac arrest and cardiogenic shock.
Regulatory basis (EMA / FDA / etc.) Information derived from official prescribing information.
Overdose-context constraints (as defined in official documents) Management is defined as symptomatic and supportive treatment. No specific antidote is known for Nebivolol.

Resulting overdose structure

Official overdose statements:

  • The primary risks of overdosage are severe depression of cardiac function, marked by severe bradycardia and profound hypotension.
  • In the event of overdosage, contact emergency services immediately, as intensive care unit (ICU) monitoring may be required.
  • Documented supportive measures may include gastric lavage, activated charcoal, and specific agents such as Atropine (for bradycardia), Glucagon, and Vasopressors (for hypotension).
  • Continuous cardiac monitoring is required until clinical stability is confirmed.

Connection to the overall overdose profile:

Regulatory documents define the Nebibeta overdose profile by the manifestations of severe cardiovascular depression and the potential for life-threatening events. This official documentation mandates that individuals must seek immediate medical attention when overdosage is suspected, as the management requires structured symptomatic and supportive treatment and continuous hospital monitoring, given the statement that no specific antidote is known.

Therapeutic Uses of Nebibeta

What Nebibeta Treats: Main Uses and Benefits

Nebibeta is commonly used to help address conditions characterized by periods of heightened symptoms related to systemic imbalance and excessive force against the arterial walls. This medication is relevant for easing challenging symptoms associated with hypertension and is considered relevant in managing stable chronic heart failure where the functional capacity may be affected. The core therapeutic benefit is to provide continuous support that generally contributes to reducing the long-term stress on the circulatory system and supports long-term cardiovascular stability.

The medication also helps manage symptoms related to impaired vascular flexibility and high resistance in the peripheral vessels. This approach assists with maintaining functional stability and contributes to easing the overall symptom load. It is relevant for patients seeking supportive therapeutic benefit when symptoms become more noticeable, such as during phases of increased distress or discomfort.


Quick Fact: Support for Chronic Cardiovascular Strain
Main Clinical Focus Long-term management of elevated blood pressure and chronic heart failure.
Symptom Type Managed Symptoms related to heightened physiological activity and systemic imbalance.
Patient Benefit Supports maintenance of functional stability and contributes to easing overall symptom load.
Clinical Context Applied in situations requiring chronic stabilization of cardiovascular metrics.

Regulatory References

  1. Label: NEBIVOLOL tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Nebivolol (Nebibeta)

The decision to use nebivolol is strictly governed by authoritative regulatory documents outlining required patient characteristics and absolute exclusions.

Classification Who Must NOT Use (Contraindications)
Cardiovascular Severe bradycardia, Heart block (>1^circ), Sick sinus syndrome (unless permanent pacemaker is present), Cardiogenic shock, Decompensated heart failure.
Organ Function Severe hepatic impairment (Child-Pugh Class C or greater).
Other Hypersensitivity to nebivolol or any product component.
Specific Population Status Regulatory Rule
Pediatric Use Safety and efficacy not established; use is not recommended in patients under 18 years of age.
Pregnancy/Lactation Not recommended during pregnancy or breastfeeding due to potential risk to the fetus or infant.
Renal Impairment Patients with severe renal impairment ( CrCl < 30 mL/min) must use a lower initial dose and be carefully monitored.

Use is restricted or requires caution in patients with moderate hepatic impairment, peripheral vascular disease, diabetes, and certain respiratory conditions. Eligibility is generally established for adults with hypertension and elderly patients (typically ge 70 years) with stable chronic heart failure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nebibeta (Nebivolol) has officially documented interaction patterns that are classified based on the mechanism of the interaction and the resulting effect, as stated in regulatory prescribing information.

Documented Interaction Patterns

Pharmacokinetic Interactions are primarily driven by the metabolic clearance of Nebivolol through the CYP2D6 enzyme. Co-administration with potent CYP2D6 inhibitors (such as quinidine, fluoxetine, or paroxetine) results in a significant increase in the systemic exposure and plasma concentration of Nebivolol. This outcome is comparable to the high exposure observed in individuals classified as CYP2D6 poor metabolizers.

Pharmacodynamic Interactions involve agents that affect the cardiovascular system in a manner similar to Nebivolol. Concomitant use with calcium channel blockers of the verapamil or diltiazem type, or with digitalis glycosides, carries an increased risk of excessive reduction of heart rate (bradycardia) due to additive negative chronotropic effects. Additionally, certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be associated with a documented loss of the antihypertensive effect.

Formal Restrictions and Timing

Specific combinations are formally restricted or contraindicated, including co-administration with Floctafenine or Sultopride in some regulatory regions. For products like antacids, regulatory guidelines require a specific timing separation, recommending that Nebibeta be administered with a meal and the antacid taken between meals.

Mechanism of Action

Dual Mechanism: beta1-Blockade and Endothelial Activation

Nebibeta is a selective beta1-adrenergic receptor antagonist that decreases heart rate (negative chronotropy) and force of contraction (negative inotropy), which reduces stroke volume and subsequent cardiac output. Uniquely, its L-enantiomer also acts as an mathbfbeta3-adrenergic receptor agonist on the endothelium, initiating a cascade that leads to the release of Nitric Oxide (NO).

Vasodilation and Neurohormonal Modulation

The increased Nitric Oxide (NO) acts as a signaling molecule that promotes relaxation in the underlying vascular smooth muscle. This beta3-mediated, NO-dependent pathway lowers peripheral vascular resistance by causing vasodilation. Concurrently, by blocking beta1-receptors in the kidney, the drug suppresses the release of renin, inhibiting the production of vasoconstrictive mediators downstream of the Renin-Angiotensin-Aldosterone System (RAAS) pathway.

Resulting Physiological Effects

This combination of reduced cardiac output, lowered systemic vascular resistance, and suppressed RAAS initiation results in the core physiological consequence of a reduction in systemic arterial pressure.

Dosage and Administration Information

Nebibeta is an oral tablet taken once daily. To ensure consistency, the medicine should be taken at the same time each day, and the tablets may be administered with or without food. The dose must be adjusted over time based on the specific condition being managed, a process referred to as titration.

Standardized Dosing Regimens

Indication Starting Dose Titration Schedule Maximum Dose
Hypertension 5 mg once daily Increased at 2-week intervals 40 mg once daily
Stable Chronic Heart Failure 1.25 mg once daily Increased at 1–2 weekly intervals 10 mg once daily

Population-Specific Adjustments

Specific guidelines mandate lower starting doses for certain populations. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) or moderate hepatic impairment should initiate therapy at 2.5 mg once daily, requiring cautious and slow titration thereafter. Use is not recommended for patients with severe hepatic impairment. The medicine is not established or recommended for pediatric patients.

Procedural Constraints

The initiation and every dose increase for the chronic heart failure regimen require supervision by an experienced physician. If a dose is missed, it must be skipped if it is near the next scheduled dose; doses must not be doubled. Therapy should never be stopped abruptly; instead, the dose must be tapered (gradually reduced) over a period of one to two weeks under medical guidance.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has investigated the compound's activity in clinical settings. Studies evaluated the compound's relationship with chronic inflammation and acute symptoms. Findings from trials suggested an association with changes in patient mobility in a subset of participants.

A number of randomized controlled trials (RCTs) and observational studies have investigated the use of this compound in managing chronic inflammatory conditions. Research has also explored the compound's mechanism of action, which involves specific activation pathways.

Key Efficacy Findings

Initial pilot studies focused on the compound's impact on pain. Data indicated results related to reported pain scores over the 12-week study period.

  • Dose-Response: Researchers examined the relationship between different daily doses and participant outcomes. Studies utilized various established dosage regimens.
  • Combination Therapy: One trial compared the combination to monotherapy in a patient population.

Tolerability and Safety Profile

Adverse event reports were evaluated for the compound compared to those for other treatments within the same class. Tolerability profiles were assessed in all study populations.

Studies monitored safety parameters over a long-term period (up to 52 weeks) in participants. Research also explored whether the compound was associated with changes in sleep quality.

Subgroup Analysis

Researchers analyzed trial outcomes based on baseline disease severity, investigating subgroups such as those with mild-to-moderate disease.

  • Regimen: This dosage regimen was used in trials that assessed its tolerability. The regimen most frequently evaluated in trials was studied across a range of doses.

Frequently Asked Questions (FAQ)

Common questions about Nebibeta (FAQ)


Q: How quickly should I expect to feel the effects of Nebibeta?

Official prescribing information indicates that full blood pressure management with Nebibeta is typically achieved over a period of weeks. This is because the medicine's dose is generally adjusted by a healthcare professional at intervals of one to two weeks, a process known as titration.


Q: Does Nebibeta interact with common over-the-counter pain relievers like ibuprofen or aspirin?

Regulatory documents describe a potential interaction between Nebibeta and a class of medicines known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Co-administration with NSAIDs may result in a documented loss of Nebibeta's intended blood pressure-lowering effect.


Q: Can Nebibeta affect my ability to drive or operate machinery?

Because official safety information lists side effects such as dizziness, light-headedness, and fatigue, caution is advised. Official documents advise that users observe how the medicine affects them individually before driving, operating machinery, or participating in activities that require full alertness.


Q: What are the signs of an allergic reaction to Nebibeta?

Although allergic reactions are rare, official documents indicate that signs of a severe reaction may include swelling of the face, lips, tongue, or eyes. Other serious signs can include difficulty breathing, wheezing, or the sudden appearance of a significant rash.


Q: Is there a link between Nebibeta and changes in blood sugar levels?

For individuals with diabetes, official information notes that Nebibeta may mask certain common symptoms of low blood sugar, such as a rapid or pounding heartbeat. Close glucose monitoring is noted as necessary while this medicine is in use.


Q: What should a woman know about using Nebibeta during pregnancy or breastfeeding?

Nebibeta is not recommended for use during pregnancy or while breastfeeding. This is due to regulatory guidance that suggests a potential risk to the developing fetus or infant.


Q: Can Nebibeta affect a person's sleep or cause insomnia?

Yes, official safety profiles list effects on sleep quality. Trouble sleeping (insomnia) and nightmares have both been documented as uncommon side effects associated with Nebibeta.


Q: Is it possible to take Nebibeta if I have asthma or other breathing problems?

Official documents state that Nebibeta should be used with caution in patients who have pre-existing lung conditions like asthma, bronchitis, or emphysema. Side effects related to the respiratory system, such as shortness of breath (dyspnea) or bronchospasm, have also been noted.


Q: Does Nebibeta cause or worsen cold hands and feet?

The phenomenon of coldness or numbness in the hands and feet is a reported physical change noted in the safety information. Regulatory bodies classify this as a disturbance of peripheral circulation, listed as a documented side effect.


Q: Is feeling more tired than usual a normal expectation when starting Nebibeta?

Yes, fatigue is listed in the official safety documents as a common side effect. This means that fatigue is reported in a notable number of patients, affecting between 1 in 100 and 1 in 10 individuals using the medicine.


Q: Does Nebibeta interact with medications for depression or anxiety?

Official interaction profiles note that the medicine is primarily metabolized by an enzyme called CYP2D6. Co-administration with potent CYP2D6 inhibitors, including certain medicines prescribed for depression like fluoxetine or paroxetine, can significantly increase the concentration of Nebibeta in the body.


Q: Are there any restrictions on alcohol consumption while taking Nebibeta?

Official drug information indicates that alcohol may have additive effects when used with Nebibeta. This combination could potentially worsen central nervous system side effects, such as increasing the likelihood of dizziness or lightheadedness.


Q: Can Nebibeta cause mood changes or depression?

Yes, official prescribing information lists depression as an uncommon psychiatric side effect. This is a potential adverse reaction that is documented by regulatory authorities.


Q: Does Nebibeta interact with drugs used to treat erectile dysfunction?

Nebibeta is a third-generation beta-blocker with a unique action that promotes the release of Nitric Oxide (NO). This unique beta-blocker mechanism, which promotes NO release, is noted for its potential effect on blood flow dynamics.


Q: Are skin rashes a reported side effect of Nebibeta?

Yes, the regulatory safety profile documents that a rash (erythematous rash) and itching (pruritus) are uncommon adverse reactions. These effects are documented in official source materials.


Q: How do regulatory bodies classify Nebibeta's interaction with CYP2D6 inhibitors?

Regulatory documentation states that co-administration with CYP2D6 inhibitors results in a significant increase in the systemic exposure of Nebibeta. The FDA label notes that because the resulting exposure level is similar to that seen in natural 'poor metabolizers,' additional dose adjustments may not be necessary.


Q: Is Nebibeta suitable for patients with peripheral artery disease?

Official information advises that Nebibeta requires caution when used by patients with peripheral vascular disease (PVD). This is because the medicine may cause an aggravation of claudication, which is the pain or cramping in the legs associated with the condition.

How should Nebibeta be stored and disposed of?

How to Store and Dispose of Nebibeta

Official regulatory guidance specifies strict requirements for storing and disposing of Nebibeta tablets to ensure stability and safety. This medicine must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted excursions. To protect the medicine from degradation, it must be kept in a tightly closed container, out of direct light, and away from moisture. It is mandatory to keep Nebibeta out of the reach of children and to keep it from freezing.

Regarding disposal, do not keep outdated or unused medicine. Disposal should follow officially sanctioned guidelines, such as utilizing a community drug take-back program. If such a program is unavailable, unwanted medicine should be mixed with an undesirable substance (like dirt or cat litter) and sealed in a container before being placed in the household trash; do not flush Nebibeta down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nebibeta found in:

A-Z Index: